Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2437 results

Sevion in antibody discovery accord with Johnson & Johnson Innovation and Janssen

22-12-2014

USA-based biopharma firm Sevion Therapeutics has entered into a collaboration agreement with CNA Development,…

BiotechnologyJanssenJohnson & JohnsonLicensingResearchSevion Therapeutics

Tiziana licenses anti-inflammatory foralumab from Novimmune

Tiziana licenses anti-inflammatory foralumab from Novimmune

22-12-2014

Oncology and immunology specialist Tiziana and antibody-based drug manufacturer Novimmune have entered…

BiotechnologyImmunologicalsLicensingNovImmuneTiziana

Roche shares fall sharply on disappointing Ph III MARIANNE study

Roche shares fall sharply on disappointing Ph III MARIANNE study

22-12-2014

Swiss pharma major Roche saw its shares plunge 6.4% to 270.40 Swiss francs on Friday following release…

BiotechnologyGenentechHerceptinKadcylaOncologyPerjetaRoche

Bina Technologies is acquired by Roche

20-12-2014

Swiss pharma giant Roche has acquired Bina Technologies, a privately held company based in Redwood City,…

Bina TechnologiesBiotechnologyMergers & AcquisitionsRoche

RXi and Hapten enter into licensing agreement for Samcyprone

RXi and Hapten enter into licensing agreement for Samcyprone

19-12-2014

RNA technology specialist RXi Pharmaceuticals Corp has entered into a global licensing agreement with…

BiotechnologyDermatologicalsLicensingNeurologicalRXi Pharmaceuticals

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

19-12-2014

US pharma major Eli Lilly and French biotech firm Adocia have entered into a worldwide licensing collaboration…

AdociaBioChaperone LisproBiotechnologyDiabetesEli LillyGlobalLicensing

Gilead and Ono enter into a licensing agreement for ONO-4059

Gilead and Ono enter into a licensing agreement for ONO-4059

19-12-2014

Japanese pharma company Ono Pharmaceutical and US biotech major Gilead Sciences have entered into a licensing…

BiotechnologyGilead SciencesLicensingOncologyOno PharmaceuticalONO-4059Research

Sorrento and Conkwest join forces on cancer immunotherapies development

Sorrento and Conkwest join forces on cancer immunotherapies development

19-12-2014

US cancer drug developer Sorrento Therapeutic and privately-held Conkwest have entered into a definitive…

BiotechnologyConkwestFinancialNeukoplastOncologyResearchSorrento Therapeutics

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Roche to acquire Austrian next-generation antibody firm Dutalys

Roche to acquire Austrian next-generation antibody firm Dutalys

19-12-2014

Swiss pharma giant Roche has agreed to acquire Dutalys, a privately held biotechnology company based…

BiotechnologyDutalysDutaMabMergers & AcquisitionsOncologyRoche

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

France Biotech presents twelfth annual Panorama of the Life Sciences survey results

18-12-2014

France Biotech, an association for life sciences entrepreneurs, has published the twelfth edition of…

BiotechnologyFrancePoliticsProductionResearch

Claritas Genomics appoints Patrick Terry as chief commercial officer

Claritas Genomics appoints Patrick Terry as chief commercial officer

18-12-2014

Genetic diagnostic lab, Claritas Genomics, has appointed Patrick Terry as chief commercial officer.

BiotechnologyBoardroomClaritas GenomicsGenomicsPatrick Terry

Amgen reveals Blincyto price as $178,000 per course

Amgen reveals Blincyto price as $178,000 per course

18-12-2014

USA-based Amgen has revealed its intended pricing for its immunotherapy Blincyto (blinatumomab), which…

AmgenBiotechnologyBlincytoOncologyPricingUSA

X-Chem licenses second cardiovascular drug discovery program to Bayer

X-Chem licenses second cardiovascular drug discovery program to Bayer

18-12-2014

Privately-held biotech firm X-Chem has licensed a second drug discovery program to German pharma major…

BayerBiotechnologyCardio-vascularLicensingX-Chem

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

16-12-2014

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have…

Anti-viralsBiotechnologyCMC BiologicsOncoSynergyOS2966ProductionResearchTropical diseases

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

16-12-2014

French autoimmune specialist Neovacs says that its Phase IIb trial of TNF-Kinoid in rheumatoid arthritis…

BiotechnologyFranceImmunologicalsNeovacsResearchTNF-Kinoid

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

16-12-2014

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities,…

BiotechnologyFranceGamaMabs PharmaOncologyResearch

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

16-12-2014

US development-stage biophama company Anthera Pharmaceuticals has entered into an exclusive licensing…

AmgenAnthera PharmaceuticalsBiotechnologyblisibimodJapanLicensingOncologyZenyaku Kogyo

Sophiris Bio shares slide on Phase III results of PRX302

Sophiris Bio shares slide on Phase III results of PRX302

16-12-2014

Biotech company Sophiris Bio saw shares in the company fall up to almost 80% following an announcement…

BiotechnologyMen's HealthPRX302ResearchSophiris Bio

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

16-12-2014

UK-based antibody therapeutics specialist Crescendo Biologics has received another equity investment…

BiotechnologyBusiness FinanceCrescendo BiologicsOncologyUK

1 to 25 of 2437 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top